Safety and feasibility of Intramuscular Dexmedetomidine for Delirium
Safety and feasibility of IntraMuscular DEXmedetomidine in reducing the incidence of delirium in at risk Intensive Care Unit patients: a pilot randomised trial
Monash Health
60 participants
Apr 7, 2025
Interventional
Conditions
Summary
This is a pilot feasibility randomized clinical trial comparing the novel intramuscular use of dexmedetomidine, an alpha-2 agonist agent, in preventing delirium and improving sleep in older, non-ventilated intensive care patients, compared with usual care. The main aims are to determine if using the drug in this context is safe, and if further, larger studies would be feasible.
Eligibility
Inclusion Criteria4
- Aged 65 or older on the day of screening.
- Expected to stay in ICU for longer than 24 hours.
- Not receiving invasive mechanical ventilation
- Arterial line in situ prior to the first dose of the drug to enable blood sampling
Exclusion Criteria23
- Any contraindication or allergy to dexmedetomidine
- Patients admitted with any form of acute neurological disturbance
- a. Suspected or proven acute primary brain injury
- b. Acute encephalopathy or altered level of consciousness
- c. Patients receiving therapy for delirium or agitation
- d. Documented history of cognitive decline or dementia
- e. Chronically receiving multiple antipsychotic medications
- Haemodynamic Concerns, defined as:
- a. Requiring significant vasopressor support
- i. Norepinephrine > 0.2 mcg/kg/min or equivalent
- b. Heart rate <50/min in the absence of a functioning pacemaker
- c. Systolic blood pressure of < 100 mmHg with or without pressor support
- Significant coagulopathy defined by either of:
- a. Platelets of < 50,000
- b. INR > 3
- Acute fulminant hepatic failure
- Pregnancy or active breastfeeding
- Incipient mortality, or moribund patient likely to die within the next 48h
- Undergoing active palliative care intervention at the end of life
- Unable to receive intramuscular injections for any reason
- Enrolled in other trials of dexmedetomidine
- Previously enrolled in this study
- Any other relevant significant clinical reason identified by the treating team
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
• A daily dose of 1 mcg/kg dexmedetomidine (max of 100 mcg). • Given intramuscularly in the deltoid or gluteal muscle between 7 – 9 pm • Administered while in the ICU for up to a maximum of five days
Locations(4)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12625000103460